2021 Articles
Volume 3 Issue 1

Letter To The Editor

Megan Oxley, MD

Volume 3 Issue 1

Letter To The Editor

Scott Allen, MD; Rachel Allen, MD

Volume 3 Issue 1

Ayahuasca Tea in the United States: Why and how?

LJ Standish ND, PhD; Juan Giménez PhD; and Victoria G Hale, PhD

Volume 3 Issue 1

Abstract:

Ayahuasca Tea is available through numerous venues. We are developing traditional Ayahuasca Tea for the group treatment of several mental health indications, including major depression, anxiety, addiction, PTSD, and unresolved grief (U.S. FDA path). We are engaging with Amazonian traditional Ayahuasceros and shamans to learn how best to develop this medicine with respect for indigenous healing rituals. Our research group has chosen to develop traditional Ayahuasca Tea—as opposed to synthesized alkaloids, or what is known as "pharmahuasca." Challenges inherent in botanical drug development as well as historical, cultural, and legal issues are discussed. The concept of reciprocity is introduced, and the Ayahuasca Tea reciprocity imperative is discussed.

 

Disclosure: 

LS, JG, and VH are employees of Sacred Medicines, a mission-driven Delaware Public Benefit Corporation

Towards Consilience Between Research Paradigms and Spiritual Practice

Thomas D. Meacham, M.D.

Volume 3 Issue 1

Abstract:

Spirituality is widely recognized as a function of health, of wholeness, and in some fashion central to psychological healing. In recent decades western medicine has found renewed interest in the spiritual aspects of healing with the development of psychedelic-assisted psychotherapy, a form of treatment commonly observed to induce spiritual and mystical experiences. Questions about the role of the mystical experience in psychological healing have led to the desire to research the subject. However, this state is well known to be difficult to study objectively due to its ineffable quality, problems with defining terms, and apparent theoretical and philosophical differences from research paradigms. This paper attempts to find the most fundamental common theoretical ground possible in order to attain consilience between research as it is performed and the spiritual experience towards the goal of improved theory and better treatment designs and clinical outcomes. This is done by conceptualizing the spiritual experience as a homeostatic mechanism to optimize the various codes of life. This places the spiritual experience in the same framework as other aspects of the social and biological sciences. As a special case, the mystical experience is conceptualized as associated with directly accessing codes created through early childhood social learning. Boundary cases and counterintuitive implications of this paradigm are discussed.

Keywords: Research, spirituality, mystical state, psychedelic-assisted psychotherapy

Volume 3 Issue 2

Editorial Review: Trial of Psilocybin versus Escitalopram for Depression

Gershom Hernandez, MD

Volume 3 Issue 2

Editorial

Is Psychedelic Therapy Integrative Medicine?

Matthew Hicks, ND, MS

Volume 3 Issue 2

Abstract:

Outside of FDA-approved clinical trials, psychedelics remain illegal though there are indications that this status will change in the coming years. An unanswered and seldom discussed question is, who will be authorized to provide psychedelic therapy? Will it only be board-certified psychiatrists and licensed psychotherapists? What about integrative providers? This paper will discuss the parallels between psychedelic medicine and integrative health, their origins, definitions, and safety.

A Comprehensive Review of Potential Uses of Ayahuasca in Psychiatry

Adam Bertroche, DO

Volume 3 Issue 2

Abstract:

Objective: This paper aims to provide a review of primarily the human studies of the use of ayahuasca for psychiatric illness and outline the pharmacology and effects of ayahuasca. 

Method: Literature review

Discussion: Ayahuasca has a unique delivery method and mechanism of action involving serotonin and sigma-1 receptors with downstream effects on dopamine and glutamate. There have been positive studies for using ayahuasca in psychiatric disorders. However, more extensive clinical trials and safety profiling are required before use in clinical practice.

Synthetic Cannabinoid-Induced Compulsive Sexual Behaviors: A Case Report

Amanda Klass, DO

Volume 3 Issue 2

Abstract:

Compulsive sexual behavior, also referred to as hypersexuality, is defined as an excessive preoccupation with sexual fantasies, urges, or behaviors that are difficult to control, cause distress, or negatively impact one’s health, job, relationship, or other parts of life [1]. Slavin et. al. explored the link between marijuana and hypersexuality and found preliminary evidence for a relationship in university students [2]. This result could be due to the interaction between the endocannabinoid and dopaminergic systems whereby behavioral-related rewards and reinforcement roles are experienced through cannabinoid-induced increases in extracellular dopamine levels [3]. This case report serves to provide data on the effects of synthetic cannabinoid-induced compulsive sexual behaviors.